New Children's Claritin(R) Grape Chewables Provide Non-Jittery, Non-Drowsy, All Day Relief For Kids' Allergy Symptoms

Helping young kids relieve their allergies during the busy back-to-school season just got easier. Schering-Plough Corporation (NYSE: SGP) today announced the introduction of CHILDREN'S CLARITIN(R) Grape Chewables, a pleasant-tasting, convenient and easy-to-take form of CHILDREN'S CLARITIN that relieves kids' worst allergy symptoms without causing jitteriness or drowsiness so they can focus on their school work -- not their allergies.

Allergies affect up to 40 percent of American children (1), who miss about two million school days a year due to bothersome symptoms (2) such as itchy, watery eyes, sneezing, and a runny nose. Some allergy medicines are labeled to take every four to six hours, which may not cover the entire school day. Some may cause drowsiness or jitters, which may challenge the ability of young students to focus at school. CHILDREN'S CLARITIN Grape Chewables provide non- drowsy, non-jittery, all day relief while kids are at school so kids don't let allergy symptoms get in the way of doing their best work.

Nurse practitioner Regina Muccio, Pediatric Specialists of Foxborough and Wrentham, Mass., will now recommend CHILDREN'S CLARITIN Grape Chewables for the trusted relief of CLARITIN(R) allergy products that parents can rely on. "The chewable tablet is easy for kids to use, so all the medicine can go down easily every time," says Muccio.

CHILDREN'S CLARITIN Grape Chewables are safe for children ages two and up (3), and adds to the portfolio of CHILDREN'S CLARITIN formulations along with CHILDREN'S CLARITIN Fruit-flavored Syrup and Grape Syrup, introduced in 2005. CLARITIN(R) RediTabs(R) Tablets are approved for children ages 6 and up. Children who feel too old for syrup but not yet ready to use adult tablets now have an option that's just right.

CHILDREN'S CLARITIN Grape Chewables will be available at stores nationwide. For more information about CHILDREN'S CLARITIN visit http://www.claritin.com.

About CLARITIN

A pediatrician recommended brand, CHILDREN'S CLARITIN allergy products include CLARITIN Syrup, the first over-the-counter non-drowsy antihistamine safe for kids as young as two years of age. CLARITIN RediTabs Tablets is a once-daily tablet that melts instantly (4) in the mouth for children ages six and up. In 2003, the FDA approved CLARITIN Hives Relief(R)tablets as the first-ever indication for the OTC relief of itching due to hives, a common skin condition, for adults and children ages six and up.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough Corporation (NYSE: SGP), a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 32,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE:

The information in this press release includes certain "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including statements relating to CLARITIN allergy products and the potential market for CLARITIN allergy products. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward- looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A. Risk Factors in the Company's second quarter 2006 10-Q.

References:
(1) American Academy of Allergy, Asthma and Immunology. The Allergy Report. Vol. I. Rochester, NY: Academic Services Consortium, University of Rochester; 2000. 1.
(2) Meltzer EO. Quality of life in adults and children with allergic rhinitis. Mosby 2001. S49.
(3) When used as directed.
(4) Speed of dissolution does not imply speed of relief.

http://www.schering-plough.com
http://www.claritin.com